---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-061771"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2026-05-15T11:05:36+00:00"
generated_at: "2026-05-15T11:10:21.653423+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma Q1 net loss $7.1M; secures up to $60M PIPE financing

## Summary
- Net loss of $7.1M ($0.53/share) vs net income of $21.5M in Q1 2025; revenue $0.
- R&D expense $4.9M (up 96% YoY) on antiviral trial milestones; cash $3.1M at March 31.
- Up to $60M private placement closed April 15 with $10M upfront, expected to fund ops into Q1 2027.
- TXM influenza prophylaxis advancing to human challenge trial in Q2 2026; FDA clinical hold unresolved.
- New hantavirus program initiated; no approved treatments exist for this disease.

## SEC filing metadata
- accession: 0001104659-26-061771
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2026-05-15T11:05:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/0001104659-26-061771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/tm2614707d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-061771
- JSON: https://secwatch.observer/filing/0001104659-26-061771.json
- Plain text: https://secwatch.observer/filing/0001104659-26-061771.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported for the quarter ended March 31, 2026 results: revenue $0.0 million, net income $7.1 million, EPS $0.53.
  - Period: for the quarter ended March 31, 2026
  - Revenue: $0.0 million
  - Net income: $7.1 million
  - EPS: $0.53
  - Result: reported results
  source text: milestone-based warrants, is sufficient to support planned expenses, including completion of the Challenge Study, into Q1 2027. Revenue for the quarter ended March 31, 2026, was $0.0 million, compared to $0.06 million for the comparable period in 2025. Research and development (R&D) expense for the quarter ended March 31, 2026, totaled $4.9 million, compared to $2.5
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465926061771/0001104659-26-061771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.